Society of Endometriosis and Uterine Disorders forum: adenomyosis today, Paris, France, December 12, 2023

Declaration of Interests W.H.C. reports consulting fees from Bayer and Sumitomo and leadership roles: Editor-in-Chief of Fertility and Sterility Science and American Board of Obstetrics and Gynecology, outside the submitted work. S.A.-S. reports personal fees from Sumitomo (formerly Myovant-Pfizer), Organon, and Bayer, outside the submitted work. M.C. has nothing to disclose. L.M. has nothing to disclose. S.A.M. reports travel support from the Society of Endometriosis and Uterine Disorders during the conduct of the study; grants and personal fees for advisory board participation from AbbVie; personal fees for advisory board participation from Roche; and personal fees for roundtable participation from Abbott, outside the submitted work. E.A.S. reports personal fees from Alnylam, AbbVie, UpToDate, WebMD, Physicians Educational Resources, MED-IQ, Myovant, Omnia, and Omnicuris; grants from National Institutes of Health (NIH) R01 HD109127-01A1 Wegienka (Principal Investigator [PI]); role as Multiple Principal Investigator; Agency for Healthcare Research and Quality/Patient-Centered Outcomes Research P50 HS23418 Myers (PI); role as Mayo Clinic site PI; NIH R01 HD105714 Nothnick (PI); role as coinvestigator; patent Methods and Compounds for Treatment of Abnormal Uterine Bleeding 6440445 issued; and unpaid advisor to the Fibroid Foundation, outside the submitted work. T.v.d.B. has nothing to disclose. C.C. has nothing to disclose. F.P. has nothing to disclose.